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Cervical cancer (CC) is the second most common 
malignancy among women worldwide, account-
ing for an estimated 0.5 million new cases and 
275,000 deaths each year [1]. The development 
of squamous cell carcinoma proceeds by distinct 
morphological changes from normal epithelium 
to carcinoma through low-grade squamous 
intraepithelial lesions (LSILs)/low-grade cervi-
cal intraepithelial neoplasia (LCIN) and high-
grade SILs (HSIL)/high-grade CIN (HCIN). 
The biological behavior of CINs varies, where 
only certain high-grade lesions progress to inva-
sive cancer when untreated [2,3]. Owing to its dis-
tinctive precancerous stages, the accessibility for 
early detection and variability in biologic pro-
gression, CC provides a paradigm for studying 
the sequential accumulation of genetic altera-
tions in tumor progression. Although infection 
with high-risk human papillomavirus (HPV) 
types has been implicated as a major etiological 
factor [4], CC as a single diagnostic entity exhib-
its differences in clinical behavior and response 
to therapy where advanced tumors poorly 
respond to chemo/radiotherapy. The stratifica-
tion of CC into subclasses for progression and 
response to treatment remain elusive. Existing 
knowledge of genetic and epigenetic alterations 
remains uninform ative in addressing the issues 
of diagnosis, tumor progression and response 
to treatment. 
Since the first description of alterations in 
chromosomal content in CC, considerable 
efforts have been made to understand the genetic 
basis of its development [5,6]. These studies have 
largely focused on gaining information on sev-
eral classes of genetic alterations, ranging from 
chromosomes to genes. These include altera-
tions in chromosome copy numbers (gains, 
losses, amplifications and rearrangements), gene 
mutations, epigenetic modifications and tran-
scriptional changes. The chromosomal trans-
location mechanism of deregulation, which is 
common in hematological and mesenchymal 
malignancies, is an uncommon or unknown 
phenomenon in CC. Despite extensive genetic 
and molecular studies, only a handful of leads 
obtained were causally implicated in CC devel-
opment. A census of genomic alterations with 
sufficient evidence (to meet the criteria for 
replicate studies, more than one study had to 
identify the change, with losses present in >20% 
cases and gains in >10%  cases) supporting a 
role in CC is presented in Tables 1 & 2 and is 
discussed in the following sections. 
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Cervical cancer (CC) as a single diagnostic entity exhibits dif ferences in 
clinical behavior and poor outcomes in response to therapy in advanced 
tumors. Although infection of high-risk human papillomavirus is recognized as 
an important initiating event in cervical tumorigenesis, stratification of CC into 
subclasses for progression and response to treatment remains elusive. Existing 
knowledge of genetic, epigenetic and transcriptional alterations is inadequate 
in addressing the issues of diagnosis, progression and response to treatment. 
Recent technological advances in high-throughput genomics and the 
application of integrative approaches have greatly accelerated gene 
discovery, facilitating the identification of molecular targets. In this article, we 
discuss the results obtained by preliminary integrative ana lysis of DNA copy 
number increases and gene expression, utilizing the two most common copy 
number-gained regions of 5p and 20q in identifying gene targets in CC. These 
analyses provide insights into the roles of genes such as RNASEN, POLS and SKP2 
on 5p, KIF3B , RALY and E2F1 at 20q11.2 and CSE1L , ZNF313 and B4GALT5 at 
20q13.13. Future integrative applications using additional datasets, such as 
mutations, DNA methylation and clinical outcomes, will raise the promise of 
accomplishing the identification of biological pathways and molecular targets 
for therapies for patients with CC.
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Genetic & epigenetic signatures of 
cervical cancer
The changes listed in Table 1 are of several classes 
of genomic alterations, resulting in copy number 
gains and losses. Amplification (≥5 copies) of 
specific regions of the genome is a common 
phenomenon in many human tumors targeting 
overexpression of dominantly acting genes [7]. 
To date, the extent of gene amplification, as 
well as the genes involved, are not completely 
realized in CC. However, upon review of the 
literature on amplifications, we identified a total 
of 20 recurrent and ten nonrecurrent amplifica-
tions (Table 1) [8,9]. A number of potential genes 
mapped to these amplicons have also been 
identi fied. However, so far, none of these were 
proven to be target genes, owing to insufficient 
biological evidence for contribution as cancer 
genes in CC. 
A similar situation exists for copy number 
changes resulting in gains (>2.5 copies) or losses 
(<1.5 copies) of specific genomic regions (Table 1). 
For simple gains of copy numbers, a large number 
(n = 21) of recurrently gained/over- represented 
regions were shown by replicate studies. Of 
these, chromosome 1 and 3q24–q29 regions 
were also shown to occur early in precancerous 
lesions [10]. Gains of several other chromosomal 
regions have been observed in single-reported 
studies in invasive CC, as well as in precancerous 
lesions. Most of these are very large regions of 
genomic gains and were not further refined by 
ana lysis in additional tumors. In the absence of 
further studies, these gains (e.g., gains of 3q and 
5p spanning larger genomic regions or even the 
entire chromosomal arm) remain u ninformative 
(Table 1) [10–12]. 
A large body of data on genetic deletions has 
been derived either by loss of heterozygosity 
or comparative genomic hybridization/array-
based studies. A large number of deleted regions 
meeting the criteria that we applied (>20% 
cases with deletion and/or confirmed by more 
than one study) have also been reported (Table 1). 
Some of these deletions were also shown to 
arise at early precancerous stages. For exam-
ple, 2q35–q37 regions of deletions spanning a 
9.5-Mb physical distance showed deletions in 
high- and low-grade CINs [8]. These findings 
of complex patterns on genetic losses suggest 
loss of function of one or more proliferation-
regulating genes in each of these regions and 
their involvement in malignant progression of 
cervical epithelium. Although the expression 
profiling allowed the identification of a sub-
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by decreased expression, no known tumor-
suppressor genes with evidence of mutations 
in the second allele have been implicated thus 
far in CC, with the exception of rare instances 
for mutations in TP53 at 17p13, CDKN2A at 
9p21 and PTEN at 10q23.3 (Tables 1 & 2). 
As stated previously, mutations in tumor- 
suppressor genes are infrequently reported 
in CC and, in most instances, the mutations 
have not been confirmed by independent 
studies (Table 2). In the absence of mutations, 
tumor-suppressor genes may be inactivated in 
the recurrently deleted chromosomal regions 
by alternative mechanisms such as epigenetic 
modifications. One of the most well- established 
epigenetic changes is the promoter DNA 
hypermethylation- mediated gene silencing. A 
large number of genes (e.g., CDH1, DAPK, 
HIC1 and PCDH10 ) exhibiting promoter 
hypermethylation and associated downregu-
lated expression of the gene have been reported 
in CC by multiple studies (Table 2) [13–16]. In 
addition, several other genes also shown to be 
methylated by a single study, where a subset of 
these cannot be completely excluded as targets 
in the deleted regions (Tables 1 & 2). 
Based on the aforementioned discussion, the 
shortness of causal genetic mutations in CC, 
although its genomes exhibit complex chromo-
somal alterations is due to insufficient evidence 
offered by these studies to identify a cancer 
gene. Several supportive studies are usually 
required to establish the role of a specific gene, 
including finer physical and transcriptional 
mapping of the altered regions, examination of 
epigenetic mechanisms, functional ana lysis of 
target genes, correlations with clinical outcome 
and efficacy of drugs targeted against specific 
genes. For most genetic alterations reported 
in CC, such studies are lacking and often not 
feasible for obtaining these data. Added to this 
complexity, molecular heterogeneity within CC 
and biologic effects of multiple genes in each of 
the affected genomic regions constitute major 
obstacles in understanding its pathogenesis. 
A number of studies have attempted using 
single high-throughput approaches to unravel 
the genetic, epigenetic and transcriptional alter-
ations in CC [17–21]. As noted previously, these 
studies have revealed specific genomic, expres-
sion and epigenetic alterations. However, the 
failure to identify target genes in CC is largely 
owing to a lack of understanding of the rela-
tionship between how copy number and epigen-
etic markers influence transcription. How each 
change influence the other (e.g., amplification 
or copy number increases on gene overexpres-
sion or methylation markers and deletions on 
downregulated gene expression) remains largely 
unknown in CC. Integrative genomic ana lyses 
involving simultaneous assessment of DNA 
copy numbers, gene expression, mutations and 
methylation markers, such as cytosine methyl-
ation and histone tail modifications, have 
been demon strated as potential approaches in 
identifying the candidate genes [22,23]. 
Cervical cancer genomes typically harbor 
multiple chromosome aberrations and epigen-
etic modifications, resulting in deregulated 
transcriptomes. These changes might play 
Table 2. Mutational and epigenetic promoter hypermethylation alteration of genes in cervical cancer.
Alteration Invasive cancer Precancerous lesions Ref.
Mutation†
Replicate studies TP53‡, CDKN2A, PTEN None Supplementary 




Replicate studies APC, CADM1, CALCA, CCNA1, CDKN2A, CDH1, 
CDH13, COX2, DAPK, FHIT, GSTP1, HIC1, MGMT, 
PCDH10, RARB, RASSF1A, THBS1, TIMP3
CDKN2A, CCNA1, DAPK, MGMT Supplementary 
online material§
Nonreplicate studies AHRR, BLU, C13ORF18, TFPI2, C1ORF166, NPTX1, 
CAGE, CDKN2B, CHFR, ESR1, TP73, ESR1, FANCF, 
HLTF1, IGSF4, MAL, MYOD1, PGR, POU2F3, 
PTEN, SOCS1, hTERT, HSPA2, MLH1, TWIST, 
SLIT1, SLIT2, SLIT3, ROBO1, ROBO3, SFRP1, 
SFRP2, SFRP4, SFRP5, SOCS2, SOX1, PAX1, 
LMX1A, NKX6–1, WT1, ONECUT1
AHRR, BLU, C13ORF18, CADM1, 
CCNA1, CDH1, CDH13, FHIT, GSTP1, 
LMX1A, MAL, hMLH1, NKX6–1, 
ONECUT1, PAX1, PCDH10, RARB, 
RASSF1A, ROBO1, ROBO3, SLIT1, SLIT2, 
SLIT3, SOCS2, SOX1, TIMP3, WT1 
†One or more cases considered positive.
‡Commonly seen in human papilloma virus-negative tumors.
§See www.futuremedicine.com/doi/suppl/10.2217/FON.10.114.
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roles in driving malignant transformation. 
Understanding the relationship between multi-
dimensional levels of genomic modifications 
might expand our knowledge of the molecular 
basis of CC. As stated previously, CC genomes 
are characterized by a number of recurrent 
genomic copy number losses and gains. Of 
those exhibiting gains, chromosomal regions 
3q, 5p, 20q and 1q were the most common tar-
gets [9,101]. In this article, we focus the ana lysis 
on two of these genomic regions in CC, 5p and 
20q, and the outcome of integrative genomic 
ana lysis using copy number increases and gene 
expression is presented. 
Genomic & transcriptional ana lysis of 
chromosomes 5p & 20q
Genomic copy number alterations (CNAs) 
were identified utilizing Affymetrix (CA, USA) 
250K NspI single nucleotide polymorphism 
(SNP) array platform and analyzed using the 
dChip analytical algorithms in 79 untreated 
primary CC samples [12,24]. Although this ana-
lysis uncovered a multitude of both known and 
unknown, as well as frequent and rare, altered 
CNAs, the 5p and 20q regions were the most 
significant recurrent focal copy number gains. 
Of these, the 5p CNA gains were found in 43% 
of tumors, and the 20q CNA gains or amplifica-
tions were found in 37% of tumors. The abun-
dance of transcripts of protein-coding genes was 
measured by the Affymetrix U133A platform 
and analyzed using the dChip software algo-
rithms among 42 CC cases [12,24]. Expression 
arrays were normalized using a median-intensity 
array from normal, as a baseline array using an 
invariant set normalization, as described pre-
viously  [12,24]. Briefly, a list of differentially 
expressed genes with a twofold change was 
identified, with group means at 90% CIs. A list 
of overexpressed genes mapped to chromosomes 
5 and 20 were identified further and used in 
subsequent supervised analyses using defined 
criteria to further obtain over expressed gene sig-
natures of specific chromo somal regions. The 
resulting gene expression datasets were utilized 
to correlate with 5p and 20q gains in order to 
identify expression patterns that were associated 
with CNAs.
Integrative genomic & transcriptional 
profiles identify target genes of 5p gains
We identified gains of the entire 5p chromosomal 
arm in CC and no minimal regions of amplifica-
tion or gain could be delineated (Figure 1a). The 
duplications of entire chromosomal arms resulting 
from isochromosome formation in human tumors 
are not uncommon (e.g., i[12p] in male testicular 
germ cell tumor [25] and i[5p][10] in several types 
of adenocarcinomas and squamous cell carci-
nomas [101,102]). Since 5p gain was one of the most 
commonly affected regions in CC genomes, which 
was validated by fluorescence in situ hybridization 
assay on a large independent cohort of tumor spec-
imens (Figure 1C), we hypothesize that the increased 
dosage of 5p may result in deregulation of genes 
that may confer oncogenic properties to its host 
cell [9]. To identify target genes of gain, we per-
formed supervised ana lyses to compare and filter 
the overexpressed 5p gene set between 5p gains 
and diploid tumors to see what extent these two 
platforms will facilitate the identification of target 
genes. This ana lysis (using a significance level of 
p < 0.05 and at least twofold increased expres-
sion) identified 17 overexpressed genes associated 
with 5p gain (Figure 1b). In addition, these genes 
showed several-fold increased expression relative 
to GAPDH in tumors with 5p gains (>2 copies) 
compared with tumors showing only two cop-
ies (Figure 1D). Therefore, these genes represent 
copy number-driven target overexpressed genes, 
which probably provide growth advantages and/or 
invasion conferred by chromosome 5p gains.
This analysis identified concurrent 5p gains, 
with overexpression of potentially relevant genes 
to cellular processes associated with tumori-
genesis, such as signal transduction (OSMR), 
nucleic acid binding, DNA repair, mitotic cycle 
(BASP1, TARS, PAIP1, BRD9, RAD1, SKP2 
and POLS), oxidative phosphorylation (NNT, 
SDHA and NDUFS6 ), HPV 16 E1 binding pro-
tein (TRIP13), ribosomal synthesis (BXDC2) and 
miRNA processing (RNASEN ). The top over-
expressed gene by this ana lysis was RNASEN 
(Drosha), which executes the initial step in 
miRNA processing by cleaving pri-miRNA to 
release pre-miRNA, and plays a major role in 
tumor progression and prognosis [26]. Muralidhar 
et al., using a similar integrative approach, have 
also identified that Drosha copy number increases 
associated with the overexpression of this gene 
in CC, and Drosha overexpression was further 
shown to influence expression of miRNAs impli-
cated in other cancer types [27]. Another gene of 
importance in cancer is OSMR, which has been 
shown to be gained and overexpressed in CC and 
is associated with adverse clinical outcome [28,29]. 
Oncostatin M is a cytokine related to the IL-6 
family of cytokines, and its biological activity is 
mediated through the receptor complex. Upon 
ligand binding, oncostatin M receptor activates 
signaling pathways implicated in cancer, such as 
Future Oncol. (2010) 6(10) future science group1648
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STAT, PI3/AKT and angiogenic factor VEGF, 
and mediates inhibition of tumor growth [30]. 
The other genes identified in this ana lysis as a 
consequence of 5p gains possess functions related 
to nucleic acid binding, DNA repair and mitotic 
cell cycle (BASP1, TARS, PAIP1, BRD9, RAD1, 
SKP2 and POLS) and nuclear genes (NNT, 
SDHA and NDUFS6 ) encoding mitochondrial 
proteins that play a role in oxidative phosphor-
ylation. Dowen et al. showed that upregulation 
of SKP2 gene transcription relates to 5p gains in 
CC cell lines [31]. SKP2 is an F-box family protein 
that plays a critical role in G1/S cell cycle progres-
sion and degrades CDKN1B (p27kip). However, 
a similar integrated gene dosage and expression 
ana lysis by Lando and coworkers found a dif-
ferent set of target genes on 5p than we identi-
fied in our study [32]. Although the exact role of 
these overexpressed genes on 5p in CC remains 
unknown, their identification provides a basis for 
dissecting the signaling cascades involving their 
role individually or synergistically as oncogenes 
in regulating the transformation in CC.
Identification of target genes of  
20q amplicons by integrative  
genomic ana lysis
Chromosome 20q has been reported to be one of 
the most common targets of NCAs in invasive 
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Figure 1. Integrated analyses of chromosome 5p genomic alterations in cervical cancer. (A) Copy number alterations in log
2
 
ratio of chromosome 5 identified by 250K NspI single nucleotide polymorphism (SNP) array in normal and tumor tissue. Each vertical 
column represents a sample with genomic regions representing from pter (top) to qter (bottom). The blue–red scale bar (-1.0 to +1.0) at 
the bottom represents the copy number changes relative to the mean across the samples. (B) Supervised ana lysis of overexpressed genes 
identified as a consequence of gain of chromosome 5p. G-banded ideogram of chromosome 5 is shown on the left. Significantly, 
differentially overexpressed genes identified between tumors showed more than two copies of 5p, and tumors with two copies of 5p are 
shown. In the matrix, each row represents the gene expression relative to group mean and each column represents a sample. Overall, as 
expected, cell lines exhibited higher levels of expression differences than primary tumors (data not shown). The scale bar (-2.0 to +2.0) 
on the bottom represents the level of expression. (C) Fluorescence in situ hybridization identification of 5p gains in invasive cancer. Green 
signals represent the 5p15.2 probe and red signals represent the probe mapping to the 5q31 region used as control. (D) Relative 
expression of differentially expressed genes as a consequence of 5p gain in relation to glyceraldehyde 3-phosphate dehydrogenase in 
normal and tumors with and without 5p gain is shown in box plot distribution. Middle line across the box represents median value, the 
upper hinge represents the 75th percentile value and the lower hinge the 25th percentile. The minimum and maximum value data points 
are shown below and above the box, respectively.
GADPH: Glyceraldehyde-3-phosphate dehydrogenase.
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development [24,34,35]. Chromosome 20q gains 
were also shown to be associated with HPV E-7-
mediated immortalization of human epithelial 
cells [36]. These data suggest that 20q amplifi-
cation is an early change in CC development, 
and the concurrent overexpression of speci fic 
gene(s) on this genomic region might be criti-
cal to transformation. Our copy number SNP 
array ana lysis of chromosome 20 identified two 
recurrent and nonoverlapping focal amplicons 
on 20q at 20q11.2 and 20q13.13 (Figure 2) [24]. 
The minimum shared region of amplicons at 
20q11.2 spans a 4.1-Mb genomic region, and 
the amplicons at 20q13.13 span a 3.1-Mb physi-
cal distance (Figure 2). Since chromo some 20q 
is one of the commonly gained regions in CC 
genomes, we hypothesize that the amplicons 
located within 20q may induce transcriptional 
activation of specific genes relevant to cellu-
lar transformation. Integrative genomic CNAs 
and expression data ana lysis identified eight 
overexpressed genes in amplicon 20q11.2 and 
six in amplicon 20q13.13 (Figure 2). The eight 
overexpressed genes in amplicon 20q11.2 are 
GSS, POFUT1, AHCY, TPX2, ASXL1, E2F1, 
RALY and KIF3B. These genes are functionally 
associated with amino acid metabolism/oxida-
tive stress (GSS and AHCY ), a Notch signal-
ing pathway (POFUT1), cell cycle regulation 
(TPX2, E2F1 and KIF3B), a putative polycomb-
group protein (ASXL1) and an RNA-binding 
protein (RALY ). The overexpressed genes in 
the interval of 20q13.13 amplicons include 
nucleotide binding (ATP9A and DDX27 ), 
activity-dependent neuroprotector (ADNP) 







































































































































































Figure 2. Chromosome 20q amplification target genes and their pathways identified by 
integrated ana lysis of copy number and gene expression. A G-banded ideogram of 
chromosome 20 is shown at the top. Representative cases of SNP array copy numbers by 250K NspI 
array in log
2
 ratio are shown. Each horizontal column in the SNP array represents a sample with 
genomic region, representing pter (top) to qter (bottom). The blue–red scale bar (-1.0 to +1.0) at the 
top represents the copy number changes relative to mean across the samples. Downward arrows show 
two focal amplicons on 20q, identified by SNP array. Significantly overexpressed genes identified and 
the pathways the genes connected as a consequence of 20q amplifications are shown in the figure. 
SNP: Single nucleotide polymorphism.
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a gene encoding for UDP-Gal:b-GlcNAc 
b-1,4- galactosyltransferase (B4GALT5) with 
transferase activity, a zinc finger protein 313 
(ZNF313) and a nuclear function protein 
(CSE1L). The genes that we found to be upreg-
ulated as a consequence of chromosome 20q 
amplifications are known to play specific roles 
in tumorigenic processes. For example, E2F1, 
KIF3B, TPX2 and CSE1L genes play pivotal 
roles in cell cycle regulation and chromosome 
segregation (Figure 2). Therefore, the genes 
identified by this approach provide a basis for 
testing their significance in relation to HPV 
infection, a functional role in tumor initiation 
and progression of CC. Recently, Lando and 
coworkers, using integrative ana lysis of gene 
dosage and expression, also found three of the 
genes (POFUT1, KIF3B and AHCY ) that we 
identified to be overexpressed as targets of 20q 
gain [32]. However, Wilting and coworkers, in 
a similar approach utilizing a smaller sample 
size and whole-genome ana lysis using differen-
tial gene locus mapping and array comparative 
genomic hybridization expression integration 
tool, did not identify any of the genes we identi-
fied in our study [37]. Therefore, these studies 
highlight the importance of the application of 
appropriate algorithms of integrative genomic 
approaches to identify gene targets that are 
biologically r elevant to cervical carcinogenesis.
Conclusion
In this article, we have described an integra-
tive genomic strategy utilizing information on 
recurrent CNAs at 5p, 20q11.2 and 20q13.13, 
with gene expression to identify genes relevant 
to genomic copy number gains and amplifica-
tions. Utilizing this approach, we demonstrated 
the robustness of this strategy in identifying 
genes and genetic pathways relevant to a specific 
region of genomic copy number increases in 
tumorigenesis. We conclusively show that a sim-
ple approach of systematic integrative genomic 
ana lysis can lead to better molecular discoveries, 
which could then be used in identifying r elevant 
therapeutic targets for CC.
Future perspective
To gain insight into molecular-based thera-
peutic targets for patients with CC, it is essen-
tial to construct an integrated view of multi-
dimensional genomic data from complementary 
technologies for CNA (gains, amplifications and 
deletions) with transcription profiles, muta-
tions, miRNA, epigenetic markers and clinical 
end points. It would be reasonable to speculate 
such an approach – complemented by appropri-
ate bioinformatics tools and functional data – is 
likely to advance our molecular knowledge to 
identify core pathways, leading to individualized 
molecular-based therapy. Advances in molecular 
knowledge will also change the detection and 
prediction of precancerous lesion, making the 
existing tests obsolete. Among the first hints at 
this approach is the integrative genomic ana-
lysis that we discussed in this article. A signi-
ficant reduction in the incidence of CC has 
been already achieved by Pap smear screening. 
The availability of a prophylactic HPV vaccine 
is expected to further reduce this incidence. 
Almost certainly, the advances in molecular and 
bioinformatic technologies will further enhance 
our molecular understanding and continue to 
raise the hope for high cure rates of CC. 
Executive summary
n	Amplification of over 20 different chromosomal regions has been reported in cervical cancer (CC).
n	CC genomes harbor multiple copy number gains and losses of specific chromosomal regions; some of these were shown to arise at 
early precancerous stages, suggesting a role for copy number alterations in its tumorigenesis. 
n	Mutational mechanisms are relatively uncommon in CC. 
n	Promoter hypermethylation and the associated downregulated gene expressions are frequent in CC.
n	The chromosomal regions of 5p and 20q exhibit the most significant recurrent focal copy number alterations in CC, suggesting their 
role in tumor formation and progression.
n	Integrative genomic ana lysis of 5p gains and 20q11.2 and 20q13.13 amplifications identified overexpressed genes as a consequence of 
genomic copy number increases. The genes identified are involved in cellular processes associated with specific pathways 
in tumorigenesis.
Financial & competing interests disclosure
Vundavalli V Murty has received funding from the 
NIH (grant number CA095647). The authors have no 
other relevant affiliations or financial involvement with 
any organization or entity with a financial interest in 
or financial conflict with the subject matter or materials 
discussed in the manuscript. This includes employment, 
consultancies, honoraria, stock ownership or options, 
expert testimony, grants or patents received or pending, 
or royalties. No writing assistance was utilized in the 
p roduction of this manuscript.
www.futuremedicine.comfuture science group 1651
Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis Review
Bibliography
Papers of special note have been highlighted as:
n  of interest
nn  of considerable interest
1. Jemal A, Siegel R, Ward E et al.: Cancer 
statistics, 2009. CA Cancer J. Clin. 59(4), 
225–249 (2009).
2. Murthy NS, Sehgal A, Satyanarayana L et al.: 
Risk factors related to biological behaviour of 
precancerous lesions of the uterine cervix. 
Br. J. Cancer 61(5), 732–736 (1990).
3. Schneider A, Koutsky LA: Natural history 
and epidemiological features of genital HPV 
infection. IARC Sci. Publ. 119, 25–52 
(1992).
4. Dunne EF, Markowitz LE: Genital human 
papillomavirus infection. Clin. Infect. Dis. 
43(5), 624–629 (2006).
5. Richart R, Ludwig AS Jr: Alterations in 
chromosomes and DNA content in 
gynecologic neoplasms. Am. J. Obstet. 
Gynecol. 104(4), 463–471 (1969).
6. Wakonig-Vaartaja R, Hughes DT: 
Chromosomal anomalies in dysplasia, 
carcinoma-in-situ, and carcinoma of cervix 
uteri. Lancet 2(7416), 756–759 (1965).
7. Santarius T, Shipley J, Brewer D et al.: 
A census of amplified and overexpressed 
human cancer genes. Nat. Rev. Cancer 10(1), 
59–64 (2010).
8. Narayan G, Arias-Pulido H, Koul S et al.: 
Genetic analysis identifies putative tumor 
suppressor sites at 2q35–q36.1 and 2q36.3–
q37.1 involved in cervical cancer progression. 
Oncogene 22(22), 3489–3499 (2003).
n	 Demonstrates the novel observation of 
deletions at 2q35–p37 regions, identifying 
a site of tumor-suppressor gene occurrence 
early in cervical cancer development.
9. Rao PH, Arias-Pulido H, Lu XY et al.: 
Chromosomal amplifications, 3q gain and 
deletions of 2q33–q37 are the frequent 
genetic changes in cervical carcinoma. BMC 
Cancer 4(1), 5 (2004).
nn	 Demonstrates, for the first time, that gene 
amplification is a frequent phenomenon in 
invasive cervical cancer.
10. Heselmeyer K, Schrock E, du Manoir S et al.: 
Gain of chromosome 3q defines the transition 
from severe dysplasia to invasive carcinoma of 
the uterine cervix. Proc. Natl Acad. Sci. USA 
93(1), 479–484 (1996).
nn	 Provides the first demonstration that gain 
of a specific chromosomal region occurs in 
cervical precancerous lesions.
11. Heselmeyer K, Macville M, Schrock E et al.: 
Advanced-stage cervical carcinomas are 
defined by a recurrent pattern of 
chromosomal aberrations revealing high 
genetic instability and a consistent gain of 
chromosome arm 3q. Genes Chromosomes 
Cancer 19(4), 233–240 (1997).
12. Scotto L, Narayan G, Nandula SV et al.: 
Integrative genomics analysis of chromosome 
5p gain in cervical cancer reveals target 
over-expressed genes, including Drosha. 
Mol. Cancer 7, 58 (2008).
n	 Identifies crucial gene-expression 
signatures as a consequence of 5p gain in 
cervical cancer.
13. Dong SM, Kim HS, Rha SH, Sidransky D: 
Promoter hypermethylation of multiple 
genes in carcinoma of the uterine  
cervix. Clin. Cancer Res. 7(7), 1982–1986 
(2001).
14. Narayan G, Scotto L, Neelakantan V et al.: 
Protocadherin PCDH10, involved in tumor 
progression, is a frequent and early target of 
promoter hypermethylation in cervical cancer. 
Genes Chromosomes Cancer 48(11), 983–992 
(2009).
15. Narayan G, Arias-Pulido H, Koul S  
et al.: Frequent promoter methylation of 
CDH1, DAPK, RARB, and HIC1 genes 
in carcinoma of cervix uteri: its relationship 
to clinical outcome. Mol. Cancer 2, 24 
(2003).
16. Virmani AK, Muller C, Rathi A et al.: 
Aberrant methylation during cervical 
carcinogenesis. Clin. Cancer Res. 7(3), 
584–589 (2001).
17. Hidalgo A, Baudis M, Petersen I et al.: 
Microarray comparative genomic 
hybridization detection of chromosomal 
imbalances in uterine cervix carcinoma. 
BMC Cancer 5, 77 (2005).
18. Wilting SM, Smeets SJ, Snijders PJ et al.: 
Genomic profiling identifies common 
HPV-associated chromosomal alterations  
in squamous cell carcinomas of cervix and 
head and neck. BMC Med. Genomics 2, 32 
(2009).
19. Kloth JN, Oosting J, van Wezel T et al.: 
Combined array-comparative genomic 
hybridization and single-nucleotide 
polymorphism-loss of heterozygosity 
analysis reveals complex genetic alterations 
in cervical cancer. BMC Genomics 8, 53 
(2007).
20. Lockwood WW, Coe BP, Williams AC, 
MacAulay C, Lam WL: Whole genome 
tiling path array CGH analysis of segmental 
copy number alterations in cervical cancer 
cell lines. Int. J. Cancer 120(2), 436–443 
(2007).
21. Fitzpatrick MA, Funk MC, Gius D et al.: 
Identification of chromosomal alterations 
important in the development of cervical 
intraepithelial neoplasia and invasive 
carcinoma using alignment of DNA 
microarray data. Gynecol. Oncol. 103(2), 
458–462 (2006).
22. Boehm JS, Zhao JJ, Yao J et al.: Integrative 
genomic approaches identify IKBKE as a 
breast cancer oncogene. Cell 129(6), 
1065–1079 (2007).
23. The TCGA Research Network: 
Comprehensive genomic characterization 
defines human glioblastoma genes and core 
pathways. Nature 455(7216), 1061–1068 
(2008).
24. Scotto L, Narayan G, Nandula SV et al.: 
Identification of copy number gain and 
overexpressed genes on chromosome arm 20q 
by an integrative genomic approach in 
cervical cancer: potential role in progression. 
Genes Chromosomes Cancer 47(9), 755–765 
(2008).
nn	 Identifies overexpression of genes involved 
in specific pathways as a consequence of 
amplifications on chromosome 20q.
25. Chaganti RS, Houldsworth J: Genetics and 
biology of adult human male germ cell tumors. 
Cancer Res. 60(6), 1475–1482 (2000).
26. Sugito N, Ishiguro H, Kuwabara Y et al.: 
RNASEN regulates cell proliferation and 
affects survival in esophageal cancer patients. 
Clin. Cancer Res. 12(24), 7322–7328 (2006).
27. Muralidhar B, Goldstein LD, Ng G et al.: 
Global microRNA profiles in cervical 
squamous cell carcinoma depend on Drosha 
expression levels. J. Pathol. 212(4), 368–377 
(2007).
28. Narayan G, Bourdon V, Chaganti S et al.: 
Gene dosage alterations revealed by cDNA 
microarray analysis in cervical cancer: 
identification of candidate amplified and 
overexpressed genes. Genes Chromosomes 
Cancer 46(4), 373–384 (2007).
n	 Demonstrates the utility of the whole-
genome approach in identifying 
recurrent copy number alterations in 
cervical cancer.
29. Ng G, Winder D, Muralidhar B et al.: Gain 
and overexpression of the oncostatin M 
receptor occur frequently in cervical 
squamous cell carcinoma and are associated 
with adverse clinical outcome. J. Pathol. 
212(3), 325–334 (2007).
30. Liu J, Hadjokas N, Mosley B et al.: 
Oncostatin M-specific receptor expression 
and function in regulating cell proliferation  
of normal and malignant mammary epithelial 
cells. Cytokine 10(4), 295–302 (1998).
31. Dowen SE, Neutze DM, Pett MR et al.: 
Amplification of chromosome 5p correlates 
with increased expression of Skp2 in 
HPV-immortalized keratinocytes. Oncogene 
22(16), 2531–2540 (2003).
Future Oncol. (2010) 6(10) future science group1652
Review Narayan & Murty
32. Lando M, Holden M, Bergersen LC et al.: 
Gene dosage, expression, and ontology analysis 
identifies driver genes in the carcinogenesis 
and chemoradioresistance of cervical cancer. 
PLoS Genet. 5(11), E1000719 (2009).
33. Wilting SM, Snijders PJ, Meijer GA et al.: 
Increased gene copy numbers at chromosome 
20q are frequent in both squamous cell 
carcinomas and adenocarcinomas of the 
cervix. J. Pathol. 209(2), 220–230 (2006).
34. Wilting SM, Steenbergen RD, Tijssen M 
et al.: Chromosomal signatures of a subset of 
high-grade premalignant cervical lesions 
closely resemble invasive carcinomas. Cancer 
Res. 69(2), 647–655 (2009).
35. Alazawi W, Pett M, Strauss S et al.: Genomic 
imbalances in 70 snap-frozen cervical 
squamous intraepithelial lesions: associations 
with lesion grade, state of the HPV16 E2 gene 
and clinical outcome. Br. J. Cancer 91(12), 
2063–2070 (2004).
36. Klingelhutz AJ, Qian Q, Phillips SL et al.: 
Amplification of the chromosome 20q region 
is associated with expression of HPV-16 E7 in 
human airway and anogenital epithelial cells. 
Virology 340(2), 237–244 (2005).
37. Wilting SM, de Wilde J, Meijer CJ et al.: 
Integrated genomic and transcriptional 
profiling identifies chromosomal loci with 
altered gene expression in cervical cancer. 






102. National Cancer Institute. Recurrent 
chromosome aberrations in cancer 
http://cgap.nci.nih.gov/Chromosomes/
RecurrentAberrations
